Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

AVIDITY BIOSCIENCES, INC.

(RNA)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-31 pm EST
23.70 USD   +4.08%
01/20Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
01/18Avidity Biosciences Says it Received FDA's Fast Track Designation for AOC 1020 to Treat Muscle-Weakening Disorder
MT
01/18Avidity Biosciences Gets FDA Fast-Track Designation for AOC 1020
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
Avidity Biosciences, Inc. is a biopharmaceutical company, which is engaged in delivering a ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The Company utilizes its AOC platform to design, engineer and develop therapeutics, which combine specificity of monoclonal antibodies (mAbs), with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with such therapeutics. Its lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1 (DM1) a rare monogenic muscle disease. The CompanyÔÇÖs advancing and expanding pipeline also includes AOC 1044, the lead of three programs for the treatment of Duchenne Muscular Dystrophy (DMD), and AOC 1020, designed to treat facioscapulohumeral muscular dystrophy (FSHD). AOC 1020 consists of its mAb, which is designed to bind to TfR1 conjugated with a siRNA targeted to DUX4 mRNA to be administered as an intravenous infusion.

Number of employees : 125 people.
Sales per Business
20202021Delta
Antibody Oligonucleotide Conjugates6.79100%9.33100% +37.41%
USD in Million
Sales per region
20202021Delta
United States6.79100%9.33100% +37.41%
USD in Million
Managers
Name Title Age Since
Sarah Boyce President, Chief Executive Officer & Director 50 2019
Michael F. MacLean Chief Financial & Accounting Officer 56 2020
Arthur A. Levin, Dr. Chief Scientific Officer 68 2019
W. Michael Flanagan, Dr. Chief Technical Officer 60 2021
Steven G. Hughes, Dr. Chief Medical Officer 55 2022
Kathleen Gallagher SVP-Corporate Communications & Investor Relations - 2021
John W. Wallen, Dr. General Counsel 64 -
Teresa McCarthy Chief Human Resources Officer - 2020
Members of the board
Name Title Age Since
Troy E. Wilson, Dr. Non-Executive Chairman 53 2021
Noreen Roth Henig, Dr. Independent Director 56 2019
Edward M. Kaye, Dr. Independent Director 73 2019
Carsten Boess Independent Director 55 2020
Tamar Thompson Independent Director 48 2021
Jean J. Kim Independent Director 48 2021
Eric B. Mosbrooker Independent Director - 2021
Sarah Boyce President, Chief Executive Officer & Director 50 2019
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 66,446,625 50,866,923 76.6% 0 0.0% 76.6%
Shareholders
NameEquities%
RA Capital Management LP 5,454,533 8.21%
Cowen & Co. LLC 5,188,366 7.81%
RTW Investments LP 5,170,784 7.78%
T. Rowe Price Associates, Inc. (Investment Management) 5,169,023 7.78%
Ecor1 Capital LLC 2,899,285 4.36%
T. Rowe Price Investment Management, Inc. 2,775,292 4.18%
Cormorant Asset Management LP 2,762,115 4.16%
The Vanguard Group, Inc. 2,630,438 3.96%
Avidity Partners Management LP 2,600,000 3.91%
Federated Global Investment Management Corp. 2,478,000 3.73%
Company contact information
Avidity Biosciences, Inc.
10578 Science Center Drive
Suite 125
San Diego, CA 92121

Phone : +1.858.401.7900
Web : http://www.aviditybiosciences.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Avidity Biosciences, Inc.